Key Drivers
- Liquidity Cushion
- Margin Stability
- Earnings Weakness
AIAI Summary
CYRX now looks like a proven growth platform with real demand and a solid balance sheet, but the stock's rerating depends on management converting that revenue momentum into operating leverage and positive free cash flow—otherwise it remains a “good story, weak earnings” setup.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Margin Stability
- •Earnings Weakness
CYRX has a solid balance sheet and strong annual 2025 profitability, but weakening quarterly revenue, losses, and negative cash flow highlight growing execution risk.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Resistance Cap
- •Momentum Cooling
CYRX has spent the last month range-bound with a constructive rebound off $14.38 that held above $15.00, but the pullback from $16.28 and repeated failure at $16.30-$16.50 leave the short-term setup neutral and dependent on a fresh catalyst for upside.
Rebounded from $14.38 to $16.28, then pulled back to $15.49, signaling fading momentum
Sentiment & News
Key News Insights:
- •Verismo selection
- •Clinical demand
- •Solid-tumor exposure
Cryoport's IntegriCell services were selected by Verismo Therapeutics for its KIR-CAR T cell therapy programs, signaling continued demand for CYRX's clinical cryopreservation platform.
This is a modest positive for CYRX, reinforcing the relevance of its temperature-controlled services in advanced cell therapy development
Similar Companies in Industrials
Other companies in the same sector with AI ratings